Vivan Therapeutics' inks New Five-Year Lease at London biotech hub White City Place

Vivan Therapeutics' inks New Five-Year Lease at London biotech hub White City Place

London, 15th October; Stanhope, the leading developer and asset manager, on behalf of the Ontario Teacher’s Pension Plan (OTPP), announces that Vivan Therapeutics, a pioneering biotech company specialising in personalised cancer treatments, has signed a new five year lease for 1,344 sq ft mixed-use office and laboratory space on the first floor in the WestWorks building at White City Place in West London.

Vivan operates a world-class research laboratory that harnesses whole animal (fruit fly) disease modelling, machine learning and high throughput drug screening to identify novel drug combinations for cancer patients. This lease renewal builds on Vivan’s significant investment in the site including custom outfit for large scale drug screening and the development of specialised robots for assay scoring. Vivan will continue to outfit the state-of-the-art facility to ramp up capacity and capabilities to service their growing customer base.

White City Place is part of a rapidly growing £4bn portfolio of office and Life Science buildings covering six million sq. ft. asset managed by Stanhope including Television Centre and Cambridge Science Park. Imperial College London, the world-class science, engineering, medicine and business university, recently joined the Mediaworks building at White City Place, joining tenants including major life sciences companies like Autolus, Novartis, and Engitix.

Laura Towart, Founder and Chief Executive of Vivan Therapeutics, says: "White City Place has been the perfect home for us over the last five years. Leveraging the local healthtech community has been invaluable in helping us grow and achieve our goals.  We are now launching our TuMatch software which can match a colorectal cancer patient’s unique tumour profile with the most effective drug therapy, often a unique personalised drug combination. We are excited to continue our journey at White City Place for the next five years and look forward to furthering our research alongside other pioneering biotech companies.”

Claire Dawe, Head of Asset Management at Stanhope, says, "We and OTPP are thrilled that Vivan Therapeutics has chosen to extend their lease with us at White City Place. The decision is a testament to the collaborative community and state-of-the-art facilities we provide, which are tailored to support the growth of innovative biotech and life sciences companies. As part of the White City Innovation District, White City Place  is rapidly becoming a cornerstone of the UK’s life sciences sector, and we are proud to support our tenants' groundbreaking work in improving cancer treatment delivery."

White City Place has rapidly emerged as a centre of excellence for life sciences and biotech innovation. Over the past two years, the campus has attracted six leading life science tenants—Engitix, Novartis, Synthace, Autolus, Vivan Therapeutics, and Invox—now totalling over 110,000 sq ft of high-quality office and lab space. This influx of pioneering companies highlights the attractiveness of White City Place as a dynamic ecosystem designed to foster collaboration, innovation, and growth.

White City Place offers a range of flexible office spaces, specialist laboratories, and collaborative environments, all designed to meet the evolving needs of biotech companies. With its strategic location, close proximity to leading research institutions like Imperial College, including the Molecular Sciences Research Hub and The Sir Michael Uren Biomedical Engineering Research Hub, and a strong focus on sustainability and innovation, White City Place is perfectly positioned to support the next generation of scientific advancements.